106 related articles for article (PubMed ID: 23446378)
1. Reduced expression of NDUFS3 and its clinical significance in serous ovarian cancer.
Wang P; Cheng X; Fu Z; Zhou C; Lu W; Xie X
Int J Gynecol Cancer; 2013 May; 23(4):622-9. PubMed ID: 23446378
[TBL] [Abstract][Full Text] [Related]
2. Response on: reduced expression of NDUFS3 and its clinical significance in serous ovarian cancer.
Piek JM
Int J Gynecol Cancer; 2013 Oct; 23(8):1348. PubMed ID: 24257547
[No Abstract] [Full Text] [Related]
3. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.
Ricciardelli C; Lokman NA; Cheruvu S; Tan IA; Ween MP; Pyragius CE; Ruszkiewicz A; Hoffmann P; Oehler MK
Clin Exp Metastasis; 2015 Jun; 32(5):441-55. PubMed ID: 25895698
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT
Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773
[TBL] [Abstract][Full Text] [Related]
5. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
6. Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas.
Zhang X; Wang X; Song X; Wei Z; Zhou C; Zhu F; Wang Q; Ma C; Zhang L
Oncol Rep; 2011 Feb; 25(2):353-8. PubMed ID: 21165576
[TBL] [Abstract][Full Text] [Related]
7. [Expression and role of glucose-regulated protein 78 in ovarian serous adenocarcinoma].
Fan LM; Su J; Dong H; Wei M; Cui MH
Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(9):659-62. PubMed ID: 23751742
[TBL] [Abstract][Full Text] [Related]
8. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
9. [Expression of THY1 gene in epithelial ovarian cancer].
Zeng LQ; Peng ZL; Duan ZL
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):118-20. PubMed ID: 19538887
[TBL] [Abstract][Full Text] [Related]
10. Retinoid receptor alpha and Beta expression in serous ovarian tumors.
Daponte A; Kostopoulou E; Papandreou CN; Chiotoglou I; Voutsadakis I; Vanakara P; Minas M; Nakou M; Kallitsaris A; Kollia P; Koukoulis G; Messinis IE
Oncology; 2007; 73(1-2):81-9. PubMed ID: 18334854
[TBL] [Abstract][Full Text] [Related]
11. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
[TBL] [Abstract][Full Text] [Related]
12. Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer.
Li YL; Ye F; Cheng XD; Hu Y; Zhou CY; Lü WG; Xie X
Eur J Cancer; 2010 Jul; 46(11):2104-18. PubMed ID: 20547056
[TBL] [Abstract][Full Text] [Related]
13. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
Nymoen DA; Holth A; Hetland Falkenthal TE; Tropé CG; Davidson B
Mol Cancer; 2015 Feb; 14():44. PubMed ID: 25889687
[TBL] [Abstract][Full Text] [Related]
14. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
[TBL] [Abstract][Full Text] [Related]
15. HSP60 predicts survival in advanced serous ovarian cancer.
Hjerpe E; Egyhazi S; Carlson J; Stolt MF; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
Int J Gynecol Cancer; 2013 Mar; 23(3):448-55. PubMed ID: 23429486
[TBL] [Abstract][Full Text] [Related]
16. Expression of Lysine-specific demethylase 1 in human epithelial ovarian cancer.
Chen C; Ge J; Lu Q; Ping G; Yang C; Fang X
J Ovarian Res; 2015 May; 8():28. PubMed ID: 25956476
[TBL] [Abstract][Full Text] [Related]
17. A centrosome clustering protein, KIFC1, predicts aggressive disease course in serous ovarian adenocarcinomas.
Mittal K; Choi DH; Klimov S; Pawar S; Kaur R; Mitra AK; Gupta MV; Sams R; Cantuaria G; Rida PCG; Aneja R
J Ovarian Res; 2016 Mar; 9():17. PubMed ID: 26992853
[TBL] [Abstract][Full Text] [Related]
18. Loss/Down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma.
Yang G; He W; Cai M; Luo F; Kung H; Guan X; Zeng Y; Xie D
Int J Gynecol Cancer; 2011 Apr; 21(3):486-93. PubMed ID: 21436696
[TBL] [Abstract][Full Text] [Related]
19. Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma.
Linder N; Bützow R; Lassus H; Lundin M; Lundin J
Gynecol Oncol; 2012 Feb; 124(2):311-8. PubMed ID: 22044687
[TBL] [Abstract][Full Text] [Related]
20. Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
Zhang J; Wang JC; Li YH; Wang RX; Fan XM
Chin Med J (Engl); 2017 Feb; 130(3):280-287. PubMed ID: 28139510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
